Menu Search
Equities

Bayer AG

BAYA:BER

Bayer AG

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (EUR)13.00
  • Today's Change-0.80 / -5.80%
  • Shares traded0.00
  • 1 Year change-25.71%
  • Beta1.2884
Data delayed at least 15 minutes, as of Feb 25 2021 14:55 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

  • Revenue in USD (TTM)51.28bn
  • Net income in USD-19.45bn
  • Incorporated--
  • Employees100.62k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301
  • Fax+49 2 143066328
  • Websitehttps://www.bayer.de/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BAYX.N:GER since
announced		Transaction
value
Asklepios BioPharmaceutical IncDeal completed26 Oct 202026 Oct 2020Deal completed21.74%4.00bn
Noho Health IncDeal completed31 Aug 202031 Aug 2020Deal completed-6.16%--
Data delayed at least 15 minutes, as of Feb 25 2021 16:07 GMT.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.